Atea Pharmaceuticals (NASDAQ: AVIR)
Atea Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Atea Pharmaceuticals Company Info
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
News & Analysis
This Dirt-Cheap Beaten-Down Biotech Stock Could Be a Diamond in the Rough -- or a Total Dud
Atea's medicine could deliver significant growth, but it won't win its market.
Why Atea Pharmaceuticals Stock Is Sinking Today
Roche calls it quits on the duo's attempt to develop an oral COVID-19 therapy.
Is There Any Hope for Atea Pharmaceuticals Stock?
If its coronavirus pill project can't be salvaged, it'll be trouble for investors.
How Atea's Clinical Flop Shakes Up the COVID-19 Pill Market
Merck and Pfizer could benefit from Atea's setback.
Was Atea Pharmaceutical's Flop Predictable?
Were warning signs there for investors all along?
Why Atea Pharmaceuticals Stock Got Crushed This Week
A mid-stage trial miss caused investors to hit the exits this week.
Why Atea Pharmaceuticals Is Imploding Today
The company's oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting.
3 Stocks to Consider if the October Stock Market Sell-Off Worsens
These stocks could be attractive at discounted prices.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.